Compare Johnson & Johnson (JNJ) vs Quantumscape Corp (QS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Johnson & Johnson vs Quantumscape Corp — how do they compare? Johnson & Johnson trades at $246.98 (market cap $598.96B), while Quantumscape Corp trades at $5.97 (market cap $3.62B). The key difference: Johnson & Johnson is far larger — about 165.5× Quantumscape Corp's market cap, and Johnson & Johnson pays a 2.15% dividend while Quantumscape Corp pays none. Which is the better fit depends on your goals.
| JNJ | QS | |
|---|---|---|
Market Cap | $598.96B | $3.62B |
Volume | 6,156,228 | — |
Sector | Health | Consumer Cyclical |
52-Week High | $267.24 | $18.44 |
52-Week Low | $164.36 | $5.86 |
Enterprise Value | $631.90B | $2.79B |
Dividend Yield | 2.15% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Johnson & Johnson (JNJ) trades at $249.58, down 1.37% today, amid a generally bullish technical outlook with strong moving average signals. The company reported robust Q2 2026 earnings, beating EPS estimates and raising full-year guidance, with revenue growth to $94.19B in 2025 and a net income margin of 21.48%. Recent news highlights strong institutional interest and positive analyst sentiment, though the stock faces pressure from MedTech segment misses despite overall strength.
The outlook for JNJ remains positive, supported by solid fundamentals, a consistent dividend history, and upward revised earnings guidance. Key risks include competitive pressures in pharmaceuticals, regulatory hurdles, and execution challenges in the MedTech division. With a consensus price target of $279.33, representing ~12% upside, the stock offers a compelling opportunity for long-term investors, balanced by sector-specific volatility and macroeconomic factors.
QuantumScape (QS) trades at $5.91, up 0.85% today, amid a bearish technical trend and negative profitability. The company reported a net loss of $435.05 million in 2025, with cash flow sustained by financing activities. Recent news highlights a joint research agreement with Honda, sparking investor interest in its solid-state battery technology.
The outlook remains speculative, hinging on successful commercialization of its battery technology. Key risks include persistent losses, high cash burn, and competitive pressures. Analyst sentiment is cautious, with no buy ratings and 72.7% hold recommendations, reflecting skepticism about near-term profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →About Quantumscape Corp
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →
